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Abstract: Neoplastic diseases are rarely described in wild carnivores; only a few reports have been 
published on this topic. Here, we describe the histological and immunohistochemical features of a 
haemangioma in the spleen of a grey wolf (Canis lupus lupus) and we compare the results with the 
dog (Canis lupus familiaris). Additionally, we list the different publications found in the literature 
with neoplastic lesions in wolves. Our results show similar immunohistochemical features to dogs, 
in which neoplastic cells express Vimentin, von Willebrand factor, alpha smooth muscle actin 
antibody, vascular endothelial growth factor C and low vascular endothelial growth factor receptor 
3. Toluidine blue special stain shows moderated increased numbers of mast cells infiltrating the 
tumor, a feature observed in benign vascular tumors in domestic dogs, but not in the malignant 
counterparts. To our knowledge, this is the first article describing the gross, histological and 
immunohistochemical features of a splenic haemangioma in a wolf. 




In contrast to studies on dogs, a limited number of reports describing tumors in wild carnivores 
are found in the literature. This is particularly noticeable in species belonging to the genus Canis, for 
which only a few reports usually referring to single cases or large surveys of populations without 
specific histopathological and immunohistochemical details are described. 
Haemangioma and haemangiosarcoma are common in dogs (Canis lupus familiaris), the dermis 
and subcutis being the most common primary sites for the haemangioma, and the spleen, skin, 
subcutis, right atrium and liver being the most common sites for haemangiosarcoma [1]. In contrast 
to dogs, only one case of a splenic haemangioma is reported in wolves; this case refers to a 10-year-
old captive red wolf (Canis rufus) with a concomitant thyroid carcinoma and two adrenal 
myelolipomas and no histological information is provided [2]. Therefore, this paper had the aim of 
describing, for the first time, the gross, histopathological and immunohistochemical characteristics of 
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a splenic haemangioma in a captive European wolf (Canis lupus lupus) and comparing the results with 
previously published studies on dogs as well as providing a list of the different publications 
describing neoplastic lesions in wolves. 
2. Materials and Methods 
2.1. Subject 
The present subject was a nine-year-old male captive European wolf (Canis lupus lupus) from a 
zoological garden that was presented for necropsy examination after it had been humanely 
euthanized due to chronic emaciation and apathy with no response to treatment. 
2.2. Pathological Investigations 
After a complete necropsy, representative tissue samples were fixed in 10%. A complete 
necropsy was performed and representative tissue samples from the main visceral organs, including 
liver, lungs, brain, spleen and splenic mass, were fixed in 10% neutral buffered formalin and routinely 
processed for paraffin embedding. Four-micron-thick sections were stained with Hematoxylin and 
Eosin, Goldner’s Trichrome and Periodic-Acid Schiff, Perls, and Toluidine Blue (TB) stains. For 
immunohistochemical investigations, four-µm-thick sections were de-waxed in xylene, hydrated 
throughout a graded series of ethanol, and rehydrated in deionized water. Antigen retrieval was 
performed with citrate buffer pH 6.0 in a microwave oven for 5 min at 750 W and 13 min at 350 W 
and cooled at room temperature. After exhausting endogenous peroxidases activity with Peroxidase 
blocking solution® (Dako, Glostrup, Denmark), non-specific reactions were blocked by incubating 
each section with two drops of Ultra V-block® (ThermoFisher Scientific; Waltham, MA, USA). 
Primary antibodies were incubated overnight in a moist chamber. The primary antibodies used were 
a mouse monoclonal anti-vimentin antibody (clone V9, dilution 1:100; Dako M0725, Glostrup, 
Denmark), a rabbit polyclonal anti-vascular endothelial growth factor C antibody (VEGFC; Zymed 
laboratories Inc., San Francisco, CA, USA), a rabbit polyclonal anti-vascular endothelial growth factor 
receptor 3 antibody (VEGFR-3; Alpha Diagnostic International, San Antonio, CA, USA), a rabbit 
polyclonal anti-von Willebrand factor antibody (vWF/Factor VIII; Dako), a mouse monoclonal anti-
alpha smooth muscle actin antibody (α-SMA; Dako), and a mouse monoclonal anti-CD44 antibody 
(Dako). After washes with Tris-buffered saline (TBS) plus and 0.1% Triton X-100 TBST, this phase 
was followed by incubation with a universal polyvalent biotinylated antibody (Horse anti 
mouse/rabbit IgG RTU, Vector Lab., Burlingame, CA, USA) for 15 min. After washing with TBST, 
streptavidin-peroxidase complex (Vector Lab. Burlingame, (CA) USA) was incubated for 15 min. 
Peroxidase activity was revealed by incubation for 10 min in 3,3′-diamonibenzidine 
tetrahydrochloride (ImmPACT DAB Peroxidase Substrate Kit®, Vector Labs inc., Burlingame, CA, 
USA) and blocked with deionized water. Finally, sections were counterstained with Mayer’s 
Haematoxylin, dried and covered with cover slips. Negative controls were performed by replacing 
the primary antibody with a unrelated mouse isotype matched control monoclonal antibody (clone 
MA5-14453; TermoFisher Scientific, Rockford, IL, USA) and a rabbit polyclonal anti-toxoplasma 
antibody. This immunohistochemical panel has been previously used in a comparative study of 
canine vascular tumors [3]. Tumors were classified according to the WHO classifications of tumors 
of domestic animals [4]. 
3. Results 
Upon macroscopic examination, the spleen exhibited a large, ~40 × 10 × 15 cm, nodular, poorly 
demarcated, mass with a similar consistency and color to the remainder of the spleen, growing from 
the ventral aspect of the organ and bulging on the surface of the organ (Figure 1A). On the cut surface, 
the mass showed numerous, variably sized, up to 1 cm in diameter, blood-filled spaces with a 
cavernous pattern (Figure 1B). The mass occupied the cranial half of the abdominal cavity and 
displaced the adjacent viscera. The remainder of the spleen appeared diffusely and severely 
congested and oozed abundant blood on cut surfaces. 
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Figure 1. Gross presentation of the splenic mass in a nine-year-old male European wolf (Canis lupus 
lupus): (A) Gross presentation of the spleen with a focal round to oval mass bulging the splenic 
capsule; (B) On the cut surface, the splenic mass shows blood-filled cavernous spaces. 
Histologically, the mass was composed of a poorly cellular, well demarcated, partially 
encapsulated and expansile neoplastic proliferation forming large blood-filled cavernous spaces 
(Figure 2A) separated by a thin fibrous stroma and lined by a single layer of spindled and flattened 
cells (neoplastic endothelial cells). Anisokaryosis and anisocytosis were mild, and no mitotic figures 
were counted in 10 high-power fields. Mixed with these large blood-filled cavernous spaces, more 
cellular areas were observed where neoplastic cells tended to give small neoplastic capillary 
structures (Figure 2B). At the periphery of the neoplastic lesion and in normal tissue entrapped within 
the neoplastic tissue there were scattered inflammatory cells, including macrophages, often with 
cytoplasmic brown granular pigment (hemosiderin; hemosiderophages) and a few lymphocytes and 
plasma cells. Inflammatory cells, mainly viable neutrophils, were occasionally observed in contact 
with the neoplastic endothelium lining neo-formed blood vessels. 
 
Figure 2. Histological photomicrograph of the splenic mass: (A) Cavernous pattern with large, regular 
and well-defined vascular spaces filled with erythrocytes (Haematoxylin-Eosin stain, Ob. 10×); (B) 
higher magnification, areas with a neoplastic capillary pattern (Haematoxylin-Eosin stain, Ob. 20×). 
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The results of immunohistochemical and histochemical investigations are presented in Figure 3. 
 
Figure 3. Immunohistochemical expression of the different markers used and the Toluidine Blue (TB) 
stain of the splenic neoplastic tissue: neoplastic cells show a positive signal for vimentin (A), von 
Willebrand factor, (B) and alpha smooth muscle actin (C) (Immunohistochemical staining, 
Haematoxylin counterstainig); (D) TB special stain showing a moderate number of infiltrating mast 
cells (arrows). 
As expected, neoplastic cells were strongly positive for vimentin (Figure 3A). The vascular origin 
of the neoplastic cells was confirmed by the diffuse expression of vWF protein, a marker for 
endothelial cells (Figure 3B) [5]. The strong α-SMA signal expressed by the neoplastic cells suggest 
an intrinsic contractile capacity of neoplastic endothelium (Figure 3C). Neoplastic endothelial cells as 
expected scored negative for CD44 antigen. A moderately increased number of mast cells (showing 
magenta staining with TB) was observed infiltrating throughout the neoplasm (Figure 3D) if 
compared to the adjacent not-affected splenic parenchyma. The other organs sampled for 
histopathology did not show evidence of micro-metastases, and the main change that was constantly 
observed was a chronic congestion mainly evident in the splenic parenchyma adjacent to the mass. 
4. Discussion 
Neoplastic lesions are rarely described in wolves and little is known about the incidence in this 
species. A list of the main publications about neoplastic diseases in wolves is made available in Table 
1, and evidence of multiple tumors in the same animal is reported. As is evident from Table 1, there 
is a higher incidence of malignant epithelial tumor (carcinomas) if compared to mesenchymal and 
round cell tumors in the species listed below. 
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Table 1. List of current publications describing neoplasm in wolves including species and main 
pathological findings. 
Species Main Findings Reference 
Mexican gray wolf 
(Canis lupus baileyi) 
Malignant mammary tumor [6] 
European wolf 
(Canis lupus lupus) 
Subcutaneous leiomyosarcoma [7] 
Polar wolf (Canis 
lupus arctos) 
Oral squamous cell carcinoma [8] 
Red wolves (Canis 
rufus) 
Two multicentric lymphomas, one mesenteric round cell tumor, one bronchial 
carcinoma and two osteosarcomas 
[2] 
American coyotes 
(Canis latrans) and 
wolves (Canis lupus). 
Oral papillomatosis [9] 
Red wolves (Canis 
rufus) 
Forty-three cases in which carcinoma or adenocarcinoma and lymphoma were the 
most common. There were also reports of pheochromocytomas, osteo-sarcomas, 
fibrosarcomas, granulosa cell tumors, sarcomas, lymphosarcomas, nerve sheath 
tumors, sertoli cell tumors, histiocytomas, and adenomas. 
[10] 
Eurasian wolf (Canis 
lupus lupus) 
Pulmonary neuroendocrine tumor [11] 
Gray wolf (Canis 
lupus) 
Papillomaviral plaque [12] 
The main gross change that could explain the clinical signs reported and that led to euthanasia 
was the massive compression of venous return from the abdominal compartment due to a large 
expansive splenic mass impeding the normal blood flow in the caudal vena cava. Since there is no 
data in literature describing histological features of vascular tumors in wolves, our results provide 
further insights on splenic hemangioma in this species. Vascular tumors are common in dogs and 
may arise in any vascularized tissue [13,14] and the most affected organs in this species are the spleen, 
right atrium and liver [15,16]. Canine hemangiosarcoma are locally infiltrative and readily 
metastasized, particularly to the lung and liver [17] and despite surgical or chemotherapeutic 
management, affected animals have a poor prognosis with a survival time little more than six months 
[18–20]. The main differential diagnosis for a large splenic mass like the one observed in the present 
case, excluding hemangioma, is splenic hematoma and hemangiosarcoma, although the latter seems 
less likely considering such a large mass not associated with clinical signs or evidence of gross and 
micro-metastases in the main organs sampled. Splenic hematoma and hemangiosarcoma are far more 
common than hemangioma in dogs (Canis lupus familiaris) [4]. This is not known in wolves; however, 
even though hemangiosarcoma has never been described in this species, the lack of publications 
makes difficult to know with certainty the real incidence. Nevertheless, our results show that the 
immunohistochemical features of the current hemangioma have clear similarities with the features 
described in dogs , in which VEGFR-3 was less expressed in benign vascular tumors (as in this case) 
and neoplastic cells show a positive signal for Vimentin, vWF, α-SMA and VEGFC. VEGFC and 
vascular endothelial growth factor D are both vascular endothelial growth factors (VEGFs) involved 
in the maintenance of normal adult endothelial cells, proliferation and the increase in vascular 
permeability and were found expressed by human vascular neoplastic cells [5,21–25]. In a previous 
study on canine vascular tumors, VEGFR-3 expression was found in the majority of 
hemagiosarcomas investigated, suggesting that this marker would not be suitable for the 
immunohistochemical discrimination between malignant and benign vascular tumors [26–28]. In 
contrast, the expression of VEGFC has been found limited to neoplastic endothelial cells in 
hemangiomas with capillary differentiation [3]. In the current case, neoplastic cells showed moderate 
intracytoplasmic positivity for VEGFC and a mild positive signal for VEGFR-3. CD44 protein is an 
adhesion molecule that plays a role in cell migration and is overexpressed in different malignant 
tumors [29]. In our study, endothelial cells of the benign vascular tumor detected in the wolf were 
also CD44-negative, confirming a previous study on canine vascular tumors where all the 
hemangiomas investigated failed to express this marker, whilst more than half of the malignant 
vascular tumors investigated were immunoreactivity for this marker [4]. CD44 can be also expressed 
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by the proliferating endothelial cells of granulation tissues, confirming their molecular similarity with 
malignant ones [3], but gross and histopathological aspects of the lesion described here allowed to 
exclude a reactive vascular proliferation. A specific immunohistochemical study for lymphatic 
endothelial markers (to rule out a neoplasm of lymphatic origin) was not performed, as moderately 
differentiated blood-filled channels, morphologically consistent with neoplastic blood vessels, 
reinforce the diagnosis of haemangioma. In dogs, the number of infiltrating mast cells was found to 
be different between malignant and benign vascular tumors; mast cells were numerous in the 
majority of hemangiomas but less commonly found in granulation tissue and hemangiosarcoma [3]. 
Interestingly, our findings show that there are indeed mast cells in moderate numbers infiltrating the 
benign neoplastic process, and this is also consistent with previous findings in dogs [3]. 
5. Conclusions 
To our knowledge, the current report describes, for the first time, gross, histological and 
immunohistochemical features of a splenic haemangioma in a wolf. Although this finding could 
suggest some differences between species, the reduced available information in literature and the 
single subject examined here limit the interpretation of our results in this species. 
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